S&P 500   4,292.75 (+0.24%)
DOW   33,765.23 (+0.01%)
QQQ   355.20 (+0.16%)
AAPL   182.82 (+1.03%)
MSFT   336.02 (+0.18%)
META   271.26 (-0.50%)
GOOGL   124.45 (-0.18%)
AMZN   124.04 (-0.17%)
TSLA   217.40 (+1.60%)
NVDA   388.65 (-1.17%)
NIO   7.69 (+1.72%)
BABA   83.93 (-0.40%)
AMD   116.21 (-1.40%)
T   15.34 (+0.85%)
F   12.68 (+2.34%)
MU   68.77 (-0.58%)
CGC   0.83 (+0.11%)
GE   105.49 (-0.29%)
DIS   90.70 (-0.08%)
AMC   4.66 (+2.42%)
PFE   38.46 (+0.26%)
PYPL   64.24 (+0.44%)
NFLX   404.43 (+0.99%)
S&P 500   4,292.75 (+0.24%)
DOW   33,765.23 (+0.01%)
QQQ   355.20 (+0.16%)
AAPL   182.82 (+1.03%)
MSFT   336.02 (+0.18%)
META   271.26 (-0.50%)
GOOGL   124.45 (-0.18%)
AMZN   124.04 (-0.17%)
TSLA   217.40 (+1.60%)
NVDA   388.65 (-1.17%)
NIO   7.69 (+1.72%)
BABA   83.93 (-0.40%)
AMD   116.21 (-1.40%)
T   15.34 (+0.85%)
F   12.68 (+2.34%)
MU   68.77 (-0.58%)
CGC   0.83 (+0.11%)
GE   105.49 (-0.29%)
DIS   90.70 (-0.08%)
AMC   4.66 (+2.42%)
PFE   38.46 (+0.26%)
PYPL   64.24 (+0.44%)
NFLX   404.43 (+0.99%)
S&P 500   4,292.75 (+0.24%)
DOW   33,765.23 (+0.01%)
QQQ   355.20 (+0.16%)
AAPL   182.82 (+1.03%)
MSFT   336.02 (+0.18%)
META   271.26 (-0.50%)
GOOGL   124.45 (-0.18%)
AMZN   124.04 (-0.17%)
TSLA   217.40 (+1.60%)
NVDA   388.65 (-1.17%)
NIO   7.69 (+1.72%)
BABA   83.93 (-0.40%)
AMD   116.21 (-1.40%)
T   15.34 (+0.85%)
F   12.68 (+2.34%)
MU   68.77 (-0.58%)
CGC   0.83 (+0.11%)
GE   105.49 (-0.29%)
DIS   90.70 (-0.08%)
AMC   4.66 (+2.42%)
PFE   38.46 (+0.26%)
PYPL   64.24 (+0.44%)
NFLX   404.43 (+0.99%)
S&P 500   4,292.75 (+0.24%)
DOW   33,765.23 (+0.01%)
QQQ   355.20 (+0.16%)
AAPL   182.82 (+1.03%)
MSFT   336.02 (+0.18%)
META   271.26 (-0.50%)
GOOGL   124.45 (-0.18%)
AMZN   124.04 (-0.17%)
TSLA   217.40 (+1.60%)
NVDA   388.65 (-1.17%)
NIO   7.69 (+1.72%)
BABA   83.93 (-0.40%)
AMD   116.21 (-1.40%)
T   15.34 (+0.85%)
F   12.68 (+2.34%)
MU   68.77 (-0.58%)
CGC   0.83 (+0.11%)
GE   105.49 (-0.29%)
DIS   90.70 (-0.08%)
AMC   4.66 (+2.42%)
PFE   38.46 (+0.26%)
PYPL   64.24 (+0.44%)
NFLX   404.43 (+0.99%)
NASDAQ:CHEK

Check-Cap (CHEK) Competitors

$1.78
+0.23 (+14.84%)
(As of 06/2/2023 06:55 PM ET)
Compare
Today's Range
$1.56
$1.78
50-Day Range
$1.30
$1.84
52-Week Range
$1.22
$9.20
Volume
72,000 shs
Average Volume
61,383 shs
Market Capitalization
$8.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00

CHEK vs. XCUR, SRGA, ICU, AEMD, BLCM, PYPD, TENX, RSLS, GLMD, and ADIL

Should you be buying Check-Cap stock or one of its competitors? The main competitors of Check-Cap include Exicure (XCUR), Surgalign (SRGA), SeaStar Medical (ICU), Aethlon Medical (AEMD), Bellicum Pharmaceuticals (BLCM), PolyPid (PYPD), Tenax Therapeutics (TENX), ReShape Lifesciences (RSLS), Galmed Pharmaceuticals (GLMD), and Adial Pharmaceuticals (ADIL). These companies are all part of the "medical" sector.

Check-Cap vs.

Check-Cap (NASDAQ:CHEK) and Exicure (NASDAQ:XCUR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, institutional ownership, earnings, analyst recommendations, community ranking, valuation and risk.

Check-Cap has a net margin of 0.00% compared to Exicure's net margin of -8.96%. Check-Cap's return on equity of -41.04% beat Exicure's return on equity.

Company Net Margins Return on Equity Return on Assets
Check-Cap N/A -41.04% -37.21%
Exicure -8.96% -66.13% -7.88%

Check-Cap received 361 more outperform votes than Exicure when rated by MarketBeat users. Likewise, 69.94% of users gave Check-Cap an outperform vote while only 47.37% of users gave Exicure an outperform vote.

CompanyUnderperformOutperform
Check-CapOutperform Votes
370
69.94%
Underperform Votes
159
30.06%
ExicureOutperform Votes
9
47.37%
Underperform Votes
10
52.63%

17.6% of Check-Cap shares are owned by institutional investors. Comparatively, 39.0% of Exicure shares are owned by institutional investors. 0.5% of Check-Cap shares are owned by company insiders. Comparatively, 3.9% of Exicure shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Exicure has higher revenue and earnings than Check-Cap. Exicure is trading at a lower price-to-earnings ratio than Check-Cap, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Check-CapN/AN/A-$19.11 million-$2.24-0.79
Exicure$28.83 million0.26-$2.58 million-$0.70-1.29

In the previous week, Check-Cap had 2 more articles in the media than Exicure. MarketBeat recorded 2 mentions for Check-Cap and 0 mentions for Exicure. Check-Cap's average media sentiment score of 0.00 equaled Exicure's average media sentiment score.

Company Overall Sentiment
Check-Cap Neutral
Exicure Neutral

Check-Cap presently has a consensus price target of $7.00, suggesting a potential upside of 293.26%. Given Check-Cap's higher possible upside, equities analysts clearly believe Check-Cap is more favorable than Exicure.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Check-Cap
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50
Exicure
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Summary

Check-Cap beats Exicure on 8 of the 14 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CHEK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CHEK vs. The Competition

MetricCheck-CapX IndustryMedical SectorNASDAQ Exchange
Market Cap$8.58M$14.86B$4.45B$6.26B
Dividend YieldN/A2.45%5.95%6.50%
P/E Ratio-0.795.2982.7311.17
Price / SalesN/A3.403,368.0487.37
Price / CashN/A9.2322.0023.57
Price / Book0.212.174.735.53
Net Income-$19.11M$267.20M$115.49M$192.15M
7 Day Performance21.92%5.32%121.56%9.32%
1 Month Performance28.06%5.35%123.55%11.03%
1 Year Performance-75.75%-30.85%135.83%1.57%

Check-Cap Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
XCUR
Exicure
0 of 5 stars
$0.86
flat
N/A-76.0%$7.17M$28.83M-1.2247Gap Up
SRGA
Surgalign
1.8611 of 5 stars
$0.77
-4.9%
$3.50
+352.8%
-82.6%$7.14M$81.98M-0.10231Positive News
Gap Up
High Trading Volume
ICU
SeaStar Medical
2.7222 of 5 stars
$0.53
+10.4%
$5.00
+843.6%
N/A$7.13MN/A0.00N/APositive News
Gap Down
AEMD
Aethlon Medical
1.5013 of 5 stars
$0.32
+3.3%
N/A-72.6%$7.25M$290,000.00-0.4310Analyst Report
BLCM
Bellicum Pharmaceuticals
0.6575 of 5 stars
$0.77
-1.3%
N/A-74.6%$7.29M$1.50M0.007Gap Down
PYPD
PolyPid
2.0834 of 5 stars
$0.38
+8.7%
$10.50
+2,700.0%
-92.1%$7.33MN/A-0.2275Positive News
Gap Up
TENX
Tenax Therapeutics
2.2016 of 5 stars
$0.32
-3.0%
$6.00
+1,775.0%
-97.2%$6.97MN/A0.008Positive News
RSLS
ReShape Lifesciences
0 of 5 stars
$2.52
-1.6%
$47.75
+1,794.8%
-94.3%$7.41M$11.24M0.0047Positive News
GLMD
Galmed Pharmaceuticals
0 of 5 stars
$4.45
-3.3%
N/A-38.0%$7.48MN/A-0.4218Earnings Report
ADIL
Adial Pharmaceuticals
2.2659 of 5 stars
$0.26
-3.7%
$3.00
+1,040.3%
-79.3%$7.50MN/A-0.5316

Related Companies and Tools

This page (NASDAQ:CHEK) was last updated on 6/5/2023 by MarketBeat.com Staff

My Account -